JP2010539192A - ノロウイルスに対して防御免疫応答を付与する方法 - Google Patents

ノロウイルスに対して防御免疫応答を付与する方法 Download PDF

Info

Publication number
JP2010539192A
JP2010539192A JP2010525114A JP2010525114A JP2010539192A JP 2010539192 A JP2010539192 A JP 2010539192A JP 2010525114 A JP2010525114 A JP 2010525114A JP 2010525114 A JP2010525114 A JP 2010525114A JP 2010539192 A JP2010539192 A JP 2010539192A
Authority
JP
Japan
Prior art keywords
norovirus
vaccine
vlp
virus
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010525114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539192A5 (cg-RX-API-DMAC10.html
Inventor
リチャードソン，チャールズ
ヴェドヴィック，トーマス，エス．
フォーベルト，トーマス，アール．
Original Assignee
リゴサイト ファーマスーティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010539192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by リゴサイト ファーマスーティカルズ，インコーポレイテッド filed Critical リゴサイト ファーマスーティカルズ，インコーポレイテッド
Publication of JP2010539192A publication Critical patent/JP2010539192A/ja
Publication of JP2010539192A5 publication Critical patent/JP2010539192A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2010525114A 2007-09-18 2008-09-18 ノロウイルスに対して防御免疫応答を付与する方法 Pending JP2010539192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97338907P 2007-09-18 2007-09-18
US98682607P 2007-11-09 2007-11-09
PCT/US2008/076763 WO2009039229A2 (en) 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014095094A Division JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法

Publications (2)

Publication Number Publication Date
JP2010539192A true JP2010539192A (ja) 2010-12-16
JP2010539192A5 JP2010539192A5 (cg-RX-API-DMAC10.html) 2011-11-04

Family

ID=40468754

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010525114A Pending JP2010539192A (ja) 2007-09-18 2008-09-18 ノロウイルスに対して防御免疫応答を付与する方法
JP2014095094A Active JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法
JP2016149168A Expired - Fee Related JP6615063B2 (ja) 2007-09-18 2016-07-29 ノロウイルスに対して防御免疫応答を付与する方法
JP2019107207A Withdrawn JP2019163328A (ja) 2007-09-18 2019-06-07 ノロウイルスに対して防御免疫応答を付与する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014095094A Active JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法
JP2016149168A Expired - Fee Related JP6615063B2 (ja) 2007-09-18 2016-07-29 ノロウイルスに対して防御免疫応答を付与する方法
JP2019107207A Withdrawn JP2019163328A (ja) 2007-09-18 2019-06-07 ノロウイルスに対して防御免疫応答を付与する方法

Country Status (9)

Country Link
US (5) US10130696B2 (cg-RX-API-DMAC10.html)
EP (1) EP2190471A4 (cg-RX-API-DMAC10.html)
JP (4) JP2010539192A (cg-RX-API-DMAC10.html)
KR (2) KR20150129042A (cg-RX-API-DMAC10.html)
CN (2) CN104740624B (cg-RX-API-DMAC10.html)
AU (1) AU2008302276B2 (cg-RX-API-DMAC10.html)
CA (1) CA2698397C (cg-RX-API-DMAC10.html)
SG (2) SG184733A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009039229A2 (cg-RX-API-DMAC10.html)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510073A (ja) * 2011-03-11 2014-04-24 マクマスター・ユニヴァーシティ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
JP2014520852A (ja) * 2011-07-11 2014-08-25 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
WO2015004995A1 (ja) * 2013-07-12 2015-01-15 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
JP2017178890A (ja) * 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
JP2018526437A (ja) * 2015-08-28 2018-09-13 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
JP2022514759A (ja) * 2018-12-20 2022-02-15 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤及び方法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
WO2010111586A2 (en) * 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
CA2804501C (en) * 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CA2851917A1 (en) * 2011-10-12 2013-04-18 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
CN102559616B (zh) * 2012-02-24 2014-01-01 河南科技大学 一种含诺如病毒rna片段的假病毒颗粒及其制备方法
KR102283760B1 (ko) * 2012-06-21 2021-08-03 노쓰웨스턴유니버시티 펩티드 접합된 입자
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
JP2016533172A (ja) 2013-10-03 2016-10-27 タケダ ワクチン，インコーポレイテッド 細胞株からラブドウイルスを検出および除去する方法
CN106456546A (zh) * 2014-03-12 2017-02-22 葛兰素史密丝克莱恩生物有限公司 用于黏膜递送的脂质体组合物
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
JP2021534074A (ja) * 2018-08-20 2021-12-09 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Ｖｌｐ製剤
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115677838A (zh) * 2021-07-29 2023-02-03 成都康华生物制品股份有限公司 六价诺如病毒VLPs疫苗及其制备方法
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
AU683211B2 (en) 1992-04-08 1997-11-06 United States of America as represented by The Secretary Department of Health and Human Services, The Wild-type measles virus glycoproteins: vaccine and detection method therefor
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ES2264126T3 (es) 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
WO1998044944A2 (en) 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
EP1105466B1 (en) 1998-08-14 2006-04-26 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
CA2354444A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
CA2375337C (en) 1999-06-22 2012-09-25 Naokazu Takeda Srsv detection kit
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CA2514667C (en) 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2006074303A2 (en) 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
ES2424229T3 (es) 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
CA2608515A1 (en) 2005-06-01 2007-05-10 Dow Global Technolgies Inc. Production of multivalent virus like particles
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CA2750321A1 (en) 2009-01-22 2010-07-29 Pharmathene, Inc. Stable vaccine compositions and methods of use
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
JP2013517773A (ja) 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ，インコーポレイテッド カリシウイルスウイルス様粒子上の標的化異種抗原提示
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
AU2016374497B2 (en) 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
SG11202010763VA (en) 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
JP2021534074A (ja) 2018-08-20 2021-12-09 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Ｖｌｐ製剤
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013004327; ＬｉｇｏＣｙｔｅ　Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，　Ｉｎｃ．: 'ＬＩＧＯＣＹＴＥ　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬＳ　ＩＮＩＴＩＡＴＥＳ　Ｕ．Ｓ．　ＣＬＩＮＩＣＡＬ　ＴＲＩＡＬ　ＯＦ　ＮＯＲＯＶＩＲＵＳ　ＶＡＣＣＩＮＥ' ［ｏｎｌｉｎｅ］ , 20070403 *
JPN6013004328; Ｖａｃｃｉｎｅ Ｖｏｌ．２１，　Ｎｏ．５-６, 2003, ｐ．３７６-３８５ *
JPN6013004329; Ｖａｃｃｉｎｅ Ｖｏｌ．２２，　Ｎｏ．９-１０, 2004, ｐ．１０７９-１０８６ *
JPN6013004330; Ｂｉｏｍｏｌｅｃｕｌａｒ　Ｅｎｇｉｎｅｅｒｉｎｇ Ｖｏｌ．１８，　Ｎｏ．３, 2001, ｐ．６９-８５ *
JPN6013004332; Ｖａｃｃｉｎｅ Ｖｏｌ．２４，　Ｎｏ．２４, 2006, ｐ．５２２０-５２３４ *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821054B2 (en) 2011-03-11 2017-11-21 Turnstone Limited Partnership Method of vaccination comprising a histone deacetylase inhibitor
JP2014510073A (ja) * 2011-03-11 2014-04-24 マクマスター・ユニヴァーシティ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
JP2014520852A (ja) * 2011-07-11 2014-08-25 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
JP2017214357A (ja) * 2011-07-11 2017-12-07 タケダ ワクチン，インコーポレイテッド 非経口ノロウイルスワクチン製剤
WO2015004995A1 (ja) * 2013-07-12 2015-01-15 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
JP2018526437A (ja) * 2015-08-28 2018-09-13 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
JP7033534B2 (ja) 2015-08-28 2022-03-10 オロジー バイオサーヴィシズ、インク． ノロウイルスワクチン
US11596680B2 (en) 2015-08-28 2023-03-07 Resilience Government Services, Inc. Norovirus vaccine
JP2017178890A (ja) * 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
US11633467B2 (en) 2018-02-15 2023-04-25 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
JP2022514759A (ja) * 2018-12-20 2022-02-15 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤及び方法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
KR20240145520A (ko) 2022-03-18 2024-10-07 덴카 주식회사 링커에 의해 연결된 캡시드 단백질을 포함하는 바이러스 유사입자

Also Published As

Publication number Publication date
US20110182975A1 (en) 2011-07-28
US20240316175A1 (en) 2024-09-26
US20190381164A1 (en) 2019-12-19
JP6615063B2 (ja) 2019-12-04
EP2190471A2 (en) 2010-06-02
JP2016196502A (ja) 2016-11-24
US20200345827A1 (en) 2020-11-05
CN104740624A (zh) 2015-07-01
CN104740624B (zh) 2018-04-24
HK1211473A1 (en) 2016-05-27
CN101918028B (zh) 2015-01-07
US11040097B2 (en) 2021-06-22
EP2190471A4 (en) 2012-05-09
SG184733A1 (en) 2012-10-30
US20220143169A1 (en) 2022-05-12
SG10201601660YA (en) 2016-04-28
WO2009039229A2 (en) 2009-03-26
US10130696B2 (en) 2018-11-20
AU2008302276B2 (en) 2013-10-10
CN101918028A (zh) 2010-12-15
AU2008302276A1 (en) 2009-03-26
US10688174B2 (en) 2020-06-23
KR20150129042A (ko) 2015-11-18
US11826415B2 (en) 2023-11-28
CA2698397C (en) 2018-03-27
WO2009039229A3 (en) 2009-09-03
KR20100083150A (ko) 2010-07-21
JP2019163328A (ja) 2019-09-26
JP6296885B2 (ja) 2018-03-20
JP2014141528A (ja) 2014-08-07
CA2698397A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
US11826415B2 (en) Method of conferring a protective immune response to Norovirus
JP6613259B2 (ja) 非経口ノロウイルスワクチン製剤
US9821049B2 (en) Method of conferring a protective immune response to Norovirus
US9861691B2 (en) Norovirus vaccine formulations
AU2014200084B2 (en) Method of conferring a protective immune response to norovirus
AU2016250345A1 (en) Method of conferring a protective immune response to norovirus
HK1211473B (en) Vaccine of conferring a protective immune response to norovirus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140502

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140707

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140815